Core Viewpoint - The company reported a revenue of 405 million RMB for the first half of 2025, representing a year-on-year growth of 20.2%, but also recorded a loss attributable to shareholders of 297 million RMB, which is an increase of 16.4% compared to the previous year [1] Group 1 - The total revenue increase is primarily attributed to the enhancement of the company's AI capabilities and industry influence [1] - The company has further penetrated multiple vertical industries with its AI solutions, leading to increased revenue in sectors such as supercomputing platforms, rail transit, and healthcare [1] - The basic loss per share is reported at 4.28 RMB [1]

Core Viewpoint - The company reported a revenue of 405 million RMB for the first half of 2025, reflecting a year-on-year growth of 20.2% [1] - However, the loss attributable to shareholders increased to 297 million RMB, a year-on-year expansion of 16.4%, with a basic loss per share of 4.28 RMB [1] Revenue Growth - The increase in total revenue is primarily attributed to the enhancement of the company's AI capabilities and industry influence [1] - The company has further penetrated multiple verticals in AI solutions, leading to revenue growth in sectors such as supercomputing platforms, rail transit, and healthcare [1]

Financial Performance - Revenue for the six months ended June 30, 2025, was RMB 404,967,000, representing a 20.2% increase compared to RMB 337,048,000 for the same period in 2024[3]. - Gross profit for the same period was RMB 130,842,000, up 13.0% from RMB 115,832,000 year-on-year[3]. - The company reported a net loss of RMB 298,330,000 for the six months ended June 30, 2025, which is a 16.6% increase in loss compared to RMB 255,758,000 in 2024[3]. - The adjusted net loss was RMB 122,448,000, reflecting a 5.2% increase from RMB 116,433,000 in the previous year[3]. - Total revenue increased by 20.2% from RMB 337,048 thousand for the six months ended June 30, 2024, to RMB 404,967 thousand for the six months ended June 30, 2025, driven by enhanced AI capabilities and industry influence[25]. - Operating expenses totaled RMB 287,254,000, compared to RMB 241,577,000 in the previous year, reflecting a 18.9% increase[67]. - The net loss for the period rose by 16.6% from RMB 255,758 thousand to RMB 298,330 thousand[35]. - The company reported a basic and diluted loss per share of RMB 4.28 for the period, compared to RMB 3.68 in the previous year[68]. Revenue Breakdown - Revenue from AI application solutions for the first half of 2025 reached RMB 404,967 thousand, a 20.1% increase from RMB 337,048 thousand in the same period of 2024[13]. - Revenue from solution sales in the first half of 2025 was RMB 282,544 thousand, representing a 22.6% growth compared to the same period in 2024[15]. - Revenue from AI chips and modules reached RMB 48,881 thousand in the first half of 2025, a 5.8% increase from the previous year[16]. - Subscription fees from API services amounted to RMB 3,243 thousand, a significant increase of 45.6% compared to the first half of 2024[17]. - Revenue from medical solutions per customer surged by 116.2% to RMB 1,013 thousand in the first half of 2025, driven by enhanced AI capabilities[18]. - Revenue from the core large language model, Shan Hai Model, increased by 457.4% to RMB 98,760 thousand in the first half of 2025[19]. - Revenue from daily life products was RMB 335,065 thousand, up 19.6% from RMB 279,881 thousand in 2024[84]. Expenses and Costs - Sales and service costs rose by 23.9% from RMB 221,216 thousand to RMB 274,125 thousand, primarily due to the expansion of AI supercomputing platform projects[26]. - Gross margin decreased from 34.4% to 32.3% due to higher hardware costs in integrated solutions[27]. - R&D expenses amounted to RMB 168,128 thousand, representing 41.5% of total revenue, with the R&D team comprising 312 employees, or 68.7% of total staff[24][32]. - Administrative expenses surged by 86.4% to RMB 57,743 thousand, largely due to increased listing expenses, which rose by 248.1% to RMB 36,618 thousand[31]. - Hardware costs increased significantly to RMB 194,411 thousand, up 60.8% from RMB 120,876 thousand in 2024[86]. Cash Flow and Financial Position - Cash and cash equivalents as of June 30, 2025, were RMB 241,693 thousand, up from RMB 156,476 thousand as of December 31, 2024, representing a growth of 54.4%[38]. - Net cash used in operating activities for the six months ended June 30, 2025, was RMB 41,360 thousand, significantly improved from RMB 175,103 thousand for the same period in 2024, indicating a reduction of 76.4%[39]. - Net cash generated from financing activities for the six months ended June 30, 2025, was RMB 131,091 thousand, compared to RMB 45,002 thousand for the same period in 2024, showing an increase of 191.2%[42]. - The company's debt-to-asset ratio decreased from 354.9% as of December 31, 2024, to 48.1% as of June 30, 2025, primarily due to the successful listing and the termination of redemption obligations[45]. - Total assets as of June 30, 2025, were RMB 1,274,822,000, an increase from RMB 1,079,976,000 at the end of 2024[69]. - The company’s total liabilities decreased to RMB 612,631,000 from RMB 3,832,884,000, indicating a significant reduction in debt levels[70]. Market and Industry Insights - The AI market in China is projected to exceed RMB 700 billion in 2024, maintaining a growth rate of over 20% for several consecutive years[4]. - The AI medical solutions market is experiencing explosive growth, particularly in areas like clinical decision support and medical imaging analysis[6]. - The company focuses on specific verticals such as home, transportation, healthcare, and insurance, leveraging deep industry knowledge and data to create targeted technological barriers[5]. - The company is actively expanding its applications in public health management and smart hardware, capitalizing on its professional AI capabilities[6]. - The industry-level knowledge graph significantly improves the accuracy and reliability of industry knowledge, reducing the hallucination phenomenon of large models[20]. Corporate Governance and Compliance - The company has adopted high standards of corporate governance to protect shareholder interests and enhance accountability[96]. - The audit committee, consisting of three members, has reviewed the unaudited interim financial information for the six months ending June 30, 2025[98]. - The company has complied with the corporate governance code since its listing date, ensuring effective internal controls and transparency[96]. - The board of directors has confirmed compliance with the standard code regarding securities trading from the listing date until the end of the reporting period[97]. - The company is committed to maintaining high standards of internal control and financial reporting practices[98]. Employee and Talent Management - As of June 30, 2025, the company has 454 full-time employees, with 68.7% in R&D, 17.6% in sales and marketing, and 13.7% in administration[59]. - Total employee compensation and benefits expenses for the six months ended June 30, 2025, amounted to RMB 95,896 thousand[61]. - The company has adopted two employee incentive plans to attract and retain talent, promoting long-term development[62]. - The company is investing in continuous education and training programs for employees to enhance skills and knowledge[60]. Future Outlook and Strategic Initiatives - The company is focused on developing new technologies and enhancing existing products to maintain market position, leveraging advanced AI technology and user feedback[24]. - The company plans to utilize the net proceeds from the listing to invest in emerging business opportunities and enhance product adoption in the industry[53]. - The company aims to achieve large model compression and chip-level inference optimization for scalable industrial applications[56]. - The company is focusing on the application of large models in serious scenarios, enhancing AI industry applications through the Beast Tooth intelligent agent platform[57]. - The intelligent medical record quality control system has upgraded from "quality control prompts" to interactive "defect modifications," establishing a commercial moat[57]. - The company has successfully implemented various industry-specific intelligent agents, significantly improving outpatient medical record entry efficiency and patient satisfaction[57]. Shareholder Information - The company has not declared an interim dividend for the six months ended June 30, 2025, nor a final dividend for the year ended December 31, 2024[65][66]. - The company has no dividends declared or paid for the periods ended June 30, 2025, and June 30, 2024[95]. - The company expresses gratitude to shareholders, management, employees, business partners, and customers for their support and contributions[100].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表 任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何 責任。 UNISOUND AI TECHNOLOGY CO., LTD. 雲知聲智能科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：9678） 公 告 取消監事會 及 建 議 修 訂《 公 司 章 程 》 取消監事會 雲知聲智能科技股份有限公司（「本公司」）董事（「董事」）會（「董事會」）謹此宣佈，根據 《中華人民共和國公司法》（「《公司法》」）、《關於新<公司法>配套制度規則實施相關過渡 期安排》等法律法規、規範性文件的規定，本公司擬不再設置監事會或監事，單波先生、 洪兆先生及任禾先生不再擔任本公司監事職務，《雲知聲智能科技股份有限公司監事會 議事規則》相應廢止，本公司各項規章制度中涉及監事會、監事的規定不再適用。 取消監事會的事項將提交本公司股東大會審議，並自本公司股東大會審議通過後生效。 上述調整生效前，本公司第二屆監事會及監事將依照法律法規和《雲知聲智能科技股份 有限公司公司章程 ...

雲知聲智能科技股份有限公司 董事會提名委員會職權範圍 第一章 總則 第一條 為規範公司董事和高級管理人員的產生，優化董事會組成，完善公司治理結 構，根據《中華人民共和國公司法》、《香港聯合交易所有限公司證券上市規則》和《雲知 聲智能科技股份有限公司章程》（以下簡稱「《公司章程》」）等有關規定，公司設立董事會 提名委員會，並制定本職權範圍。 第二條 董事會提名委員會是董事會設立的專門工作機構，主要負責對公司董事、總經 理和其他高級管理人員的人選、甄選標準和程序等事項進行選擇並提出建議。 第三條 《公司法》和《公司章程》關於董事義務的規定適用於提名委員會委員。 第二章 人員組成 第四條 提名委員會由至少3名董事組成，其中獨立非執行董事佔多數，且至少一名成 員的性別須與提名委員會成員不同。 第五條 提名委員會委員由董事長、二分之一以上獨立非執行董事或者全體董事的三 分之一以上提名，並由董事會選舉產生。 第六條 提名委員會設主席一名，由獨立非執行董事或董事會主席擔任，主席負責主持 委員會工作，擔任召集人，主席由董事會批准產生。 第七條 提名委員會任期與董事會任期一致，委員任期屆滿，連選可以連任。期間如有 委員不再擔任 ...

Core Viewpoint - Company Yunzhisheng (09678) has been selected for inclusion in various Hang Seng Index series, effective from September 8, 2025, which is expected to enhance its investment value and reputation in the capital market [1] Group 1: Inclusion in Hang Seng Index - Company will be included in the following Hang Seng Index series: 1. Hang Seng Composite Index; 2. Hang Seng Composite Industry Index - Information Technology; 3. Hang Seng Composite Small Cap Index; 4. Hang Seng Composite Small Cap Index; 5. Hang Seng Internet Technology Index; 6. Hang Seng Information Technology Index; 7. Hang Seng Information Technology (Investable) Index; 8. Hang Seng Hong Kong Stock Connect Information Technology Index; 9. Hang Seng Hong Kong Stock Connect Software and Semiconductor (Investable) Index; 10. Hang Seng Hong Kong Stock Connect Software and Semiconductor Index [1] Group 2: Impact on Company - Inclusion in the Hang Seng Composite Index is expected to help expand the shareholder base, thereby increasing the company's investment value and reputation in the capital market [1]

Core Viewpoint - The company Yunzhisheng (09678) has been selected to be included in various Hang Seng Index series, effective from September 8, 2025, which is expected to enhance its investment value and reputation in the capital market [1]. Group 1 - The company will be included in the following Hang Seng Index series: 1. Hang Seng Composite Index; 2. Hang Seng Composite Industry Index - Information Technology; 3. Hang Seng Composite Small Cap Index; 4. Hang Seng Composite Micro Cap Index; 5. Hang Seng Internet Technology Index; 6. Hang Seng Information Technology Index; 7. Hang Seng Information Technology (Investable) Index; 8. Hang Seng Hong Kong Stock Connect Information Technology Index; 9. Hang Seng Hong Kong Stock Connect Software and Semiconductor (Investable) Index; 10. Hang Seng Hong Kong Stock Connect Software and Semiconductor Index [1]. - The Hang Seng Index series is widely referenced and reflects the performance of the Hong Kong stock market [1]. - The board believes that inclusion in the Hang Seng Composite Index will help expand the shareholder base [1].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表 任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何 責任。 UNISOUND AI TECHNOLOGY CO., LTD. 雲知聲智能科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：9678） 自願性公告 納入恒生指數系列成份股 本公告乃由雲知聲智能科技股份有限公司（「本公司」）自願作出。 本公司董事會（「董事會」）欣然宣佈，本公司已獲恒生指數有限公司選定並將納入下列 恒生指數系列之成份股，自2025年9月8日起生效： 恒生指數系列是獲廣泛引用及反映香港股票市場表現的重要指標。董事會認為，獲納入 恒生綜合指數，將有助於擴大股東基礎，從而提高本公司於資本市場的投資價值及聲 譽。進一步詳情請參閱恒生指數有限公司網站( https://www.hsi.com.hk )刊登的相關指數通 告。 1 2 1. 恒生綜合指數； 2. 恒生綜合行業指數 — 資訊科技業； 3. 恒生綜合中小型股指數； 4. 恒生綜合小型股指數； 5. 恒生互聯網科技業指 ...

8月22日，恒生指数公司宣布截至2025年6月30日之恒生指数系列季度检讨结果，其中云知声(09678)获 纳入恒生综合指数，变动将于9月5日(星期五)收市后实施并于9月8日(星期一)起生效，届时沪深交易所 会相应调整港股通可投资标的范围。据华泰证券研报，云知声有可能被调入港股通，因其满足了包括市 值、流动性和上市时间等在内的一系列标准。 国证国际此前指出，公司技术实力较强：拥有自研600亿参数的"山海大模型"，在医疗领域MedBench评 测排名第一，技术能力获得行业认可。场景应用广泛：业务覆盖智慧生活和医疗AI两大场景。在智慧 生活领域，其语音交互系统应用于智慧住宅、商业空间、地铁等场景;在医疗AI领域，提供病历语音输 入、质控系统等，服务166家医院，能有效提升录入效率和质控水平。 今年7月，云知声与南太平洋数字科技控股正式签署了关于人工智能技术应用合作的谅解备忘录，并将 建立长期合作，将通用人工智能技术应用于面向稳定币的发行管理等智慧金融领域的技术支持，共同推 动数字资产等相关数字金融技术的创新与应用。 ...

Group 1 - The Hang Seng Index Company announced the inclusion of Yunzhisheng (09678) in the Hang Seng Composite Index, effective from September 8, 2025, following the quarterly review on June 30, 2025 [1] - Yunzhisheng is likely to be included in the Hong Kong Stock Connect due to meeting various criteria such as market capitalization, liquidity, and listing duration [1] - The company signed a memorandum of understanding with South Pacific Digital Technology Holdings in July 2023 to collaborate on the application of artificial intelligence technology in the issuance and management of stablecoins [1] Group 2 - Guozheng International highlighted the strong technical capabilities of Yunzhisheng, which has developed a self-researched model with 60 billion parameters, ranking first in the MedBench evaluation in the medical field [1] - The company's applications are widespread, covering smart living and medical AI, with voice interaction systems used in smart homes, commercial spaces, and subways [1] - In the medical AI sector, Yunzhisheng provides voice input and quality control systems to 166 hospitals, significantly improving input efficiency and quality control levels [1]